Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2009

View Archived Issues

GABA receptor inverse agonist shows potential in in vivo models of Alzheimer's

ProteoTech reports on small molecule targeting alpha-synuclein aggregation for Parkinson's disease

MHRA accepts BioMarin's CTA for phase I/II clinical trial of BMN-110 in MPS IVA

Cryopyrin-associated periodic syndrome remission seen with canakinumab in phase III study

Valeant Pharmaceuticals International presents novel potassium channel modulators

Lipoxen and Glide collaborate to investigate delivery of SuliXen with Glide technology

Innocoll investigates CollaRx gentamicin surgical implant in phase III trial

Genzyme receives positive opinion for Renvela in patients with kidney disease

Glivec recommended for use in Europe in postsurgery gastrointestinal tumors

Qutenza receives positive CHMP recommendation for neuropathic pain

Alchemia and SDP enter drug discovery agreement for anticancer drugs targeting SK1

SciClone completes patient enrollment in phase II trial of pancreatic cancer drug RP-101

Starpharma completes patient testing in clinical trial of topical microbicide VivaGel

FDA issues letter to Oxygen outlining path forward to resume clinical studies of Oxycyte

Bristol-Myers Squibb withdraws marketing authorization application for Ixempra

FDA Advisory Committee supports rivaroxaban's favorable risk-benefit profile

Enzon initiates treatment of patients with survivin antagonist EZN-3042 under IND

Poniard to focus resources on oncology drug picoplatin

Sirion's sNDA for Durezol for uveitis is accepted for review by the FDA

Novel naphthalene derivatives patented by Servier

Pfizer reports on development, pharmacological profile of PF-2413873

Novel, orally bioavailable compound for the treatment of migraine presented by Merck

Novel cannabinoid 2 receptor agonists reported by Merck & Co.

Novel imidazopyrazine compounds discovered by BioFocus

Merck presents novel selective androgen receptor modulator

Characteristics of gamma-secretase inhibitor BMS-708163 detailed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...